Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After A Brief Pause, Injectables Cash Cow Agila Is Back Into Production; Pfizer Expects Shipping To Commence Soon

This article was originally published in PharmAsia News

Executive Summary

Agila, as its name suggests, was agile in correcting deficiencies outlined in an FDA 483 last month and is back on track to supply global customers like Pfizer, GSK and Eli Lilly. But Mylan’s planned buyout of Agila, Strides Arcolab’s cash cow, has hit a snag and been put on hold by India’s finance ministry.

Advertisement

Related Content

Mylan’s Autor-de-Force Move into Quality “Differentiation” and Sterile Injectables
Form 483 Reply Can Be Ticket To FDA’s Good Side – Attorney
Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes
India Story Tempered? Government May Put Future Brownfield Buyouts Under Scrutiny; No Qualms On Greenfield Investments

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC084824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel